Journal Mobile Options
Table of Contents
Vol. 198, No. 3, 1999
Issue release date: 1999
Dermatology 1999;198:261–264

Cigarette Smoking as a Triggering Factor of Hidradenitis suppurativa

König A. · Lehmann C. · Rompel R. · Happle R.
Departments of Dermatology,aPhilipp University, Marburg, and bStädtische Kliniken, Kassel, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Hidradenitis suppurativa is a chronic inflammatory skin disease involving the axillary, inguinal and anogenital regions and sometimes, in addition, the submammary or sacral areas. The etiology of this condition is unknown. Objective: A matched-pair case-control study was performed to evaluate the influence of smoking habits on the manifestation of this disease. Methods: Patients who had received surgical treatment for hidradenitis suppurativa in two dermatological centers completed a questionnaire dealing with family history, course of the disease and smoking habits. To form a randomized matched-pair control group, an equal number of patients admitted for various other skin diseases such as atopic dermatitis, varicose veins, skin tattoos, alopecia areata or melanoma was matched for sex and age and evaluated for smoking habits. Statistical analysis was performed by use of several χ2 tests in a cross-table setting. Moreover, a comparison to the expected smoking prevalence in Germany based on national statistics was performed. Results: Out of 84 patients treated for hidradenitis suppurativa, 63 subjects (27 men, 36 women) completed the questionnaire. The rate of active cigarette smokers was 88.9% (56 patients), whereas 4 subjects (6.4%) had never smoked. 3 patients (4.8%) stated to be ex-smokers, but 2 of these had quit smoking only recently and after onset of the disease. The rate of smokers in the matched-pair control group was 46%. The significantly higher proportion of active smokers among patients with hidradenitis suppurativa can be expressed by an odds ratio of 9.4, the calculated 95% confidence interval was 3.7–23.7 (p < 0.001). The expected smoking prevalence in Germany was 26.7% according to national statistics. 73% of our patients had no family history of hidradenitis suppurativa whereas 27% reported at least one affected first-degree relative. Conclusion: From the exceedingly high rate of smokers among patients with this condition we conclude that cigarette smoking is a major triggering factor of hidradenitis suppurativa. Remarkably, the disease can be categorized as a smoking sequel that is neither of vascular nor neoplastic nature. Because familial occurrence was rather rarely reported, and because an environmental factor in the form of cigarette smoking appears to be of crucial importance to trigger the disease, we assume that the genetic basis of hidradenitis suppurativa is polygenic rather than mendelian. Smoking cessation should be encouraged particularly in patients with hidradenitis suppurativa although it is unknown whether this improves the course of the disease.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Yu CC, Cook MG: Hidradenitis suppurativa: A disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 1990;122:763– 769.
  2. Boer J, Weltevreden EF: Hidradenitis suppurativa or acne inversa: A clinicopathological study of early lesions. Br J Dermatol 1996;135: 721–725.
  3. Plewig G, Steger M: Acne inversa (alias acne triad, acne tetrad or hidradenitis suppurativa); in Marks R, Plewig G (eds): Acne and Related Disorders. London, Dunitz, 1988, pp 345–357.
  4. Jemec GBE, Heidenheim M, Nielsen NH: The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996;35:191–194.

    External Resources

  5. Banerjee AK: Surgical treatment of hidradenitis suppurativa. Br J Surg 1992;79:863–866.
  6. Fitzsimmons JS, Guilbert PR: A family study of hidradenitis suppurativa. J Med Genet 1985; 22:367–373.
  7. Jemec GBE: The symptomatology of hidradenitis suppurativa in women. Br J Dermatol 1988;119:345–350.
  8. Küster W, Rödder-Wehrmann O, Plewig G: Acne inversa: Pathogenese und Genetik. Hautarzt 1991;42:2–4.
  9. Breitkopf C, Bockhorst J, Lippold A, Ernst K, Hundeiker M: Pyodermia fistulans sinifica (Akne inversa) und Rauchgewohnheiten. Z Hautkr 1995;70:332–334.
  10. Statistisches Bundesamt Wiesbaden: Rauchgewohnheiten im April 1995. Gesundheitswesen Fachserie 12, Reihe S3. Stuttgart, Metzler-Poeschel, 1996, pp 62–134.
  11. Wiltz O, Schoetz DJ Jr, Murray JJ, Roberts PL, Coller JA, Veidenheimer MC: Perianal hidradenitis suppurativa: The Lahey experience. Dis Colon Rectum 1990;33:731–734.
  12. O’Doherty CJ, MacIntyre C: Palmoplantar pustulosis and smoking. Br Med J 1985;291:861– 864.
  13. Eriksson M-O, Hagforsen E, Lundin IP, Michaëlsson G: Palmoplantar pustulosis: A clinical and immunohistological study. Br J Dermatol 1998;138:390–398.
  14. Smith JB, Fenske NA: Cutaneous manifestations and consequences of smoking. J Am Acad Dermatol 1996;34:717–732.
  15. Mills CM, Finlay AY: Does smoking influence acne? Clin Exp Dermatol 1993;18:100–101.

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00